Sai Life Sciences Limited
CLOSEDIPO Date: 11 Dec - 13 Dec 2024
Listing Date: 18 Dec 2024
Price Range
₹522 to ₹549
Issue Size
3042.62 Cr
Min Investment
₹14,094
Lot Size
27 Shares
Schedule of Sai Life Sciences Limited
Issue open date
11 Dec 2024
Issue close date
13 Dec 2024
UPI mandate deadline
13 Dec 2024 (5 PM)
Allotment finalization
16 Dec 2024
Share credit
17 Dec 2024
Listing date
18 Dec 2024
Mandate end date
28 Dec 2024
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 3042.62 Cr |
| Fresh Issue | 0 Cr |
| Offer for Sale | 3042.62 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 16 Dec 2024 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 18 Dec 2024 | ₹549 | ₹72 | ₹621 (13.11%) |
| 17 Dec 2024 | ₹549 | ₹72 | ₹621 (13.11%) |
| 16 Dec 2024 | ₹549 | ₹70 | ₹619 (12.75%) |
| 15 Dec 2024 | ₹549 | ₹61 | ₹610 (11.11%) |
| 14 Dec 2024 | ₹549 | ₹63 | ₹612 (11.48%) |
| 13 Dec 2024 | ₹549 | ₹42 | ₹591 (7.65%) |
| 12 Dec 2024 | ₹549 | ₹19 | ₹568 (3.46%) |
| 11 Dec 2024 | ₹549 | ₹39 | ₹588 (7.1%) |
| 10 Dec 2024 | ₹549 | ₹31 | ₹580 (5.65%) |
| 9 Dec 2024 | ₹549 | ₹28 | ₹577 (5.1%) |
| 8 Dec 2024 | ₹549 | ₹42 | ₹591 (7.65%) |
Performance Sai Life Sciences Limited
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹522 to ₹549 | ₹ 4743 (39.28%) | ₹ 684.75 | 24.73% |
About Sai Life Sciences Limited
Sai Life Sciences Limited is a global innovation-focused CRDMO, offering end-to-end services for small molecule drug discovery, development, and manufacturing. Serving over 280 pharmaceutical innovators, including 18 of the top 25 global pharma companies, it operates state-of-the-art research labs in the US and UK, and large-scale facilities in India. The company provides integrated CRO services in biology, chemistry, and DMPK, supporting 140+ discovery programs and numerous IND filings in the past five years. Its CDMO division specializes in API development and manufacturing, with a portfolio of 38 APIs used in 28 commercial drugs, including seven blockbuster drugs. Sai Life Sciences' facilities are accredited by global regulatory bodies like USFDA and PMDA. With a focus on sustainability, it utilizes renewable energy and is a PSCI member. From FY 2022–2024, it achieved a revenue CAGR of 29.8% and EBITDA CAGR of 51.32%, demonstrating strong financial growth.
| Founded in | 1999 |
| Managing director | KRISHNAMRAJU KANUMURI, RUNA KARAN, SIVARAMAKRISHNAN CHITTOR, RANGA RAJU KANUMURI, KRISHNAMRAJU KANUMURI, RAMESH GANESH IYER and MITESH DAGA. |
| Parent organization | TPG Asia VII SF Pte Ltd |
Financial Overview
Strengths
- Sai Life Sciences Limited has a diverse portfolio of drugs and APIs and is among the fastest-growing Indian CRDMOs.
- Integrated discovery capabilities in biology chemistry and DMPK are attracting more customers.
- Strong relationships with top pharmaceutical companies and modern R&D infrastructure support growth.
Risks
- Reliance on the biotechnology and pharmaceutical industries makes the company vulnerable to external trends.
- High costs and risks in research and development could threaten future growth.
- Failure to comply with regulations or meet customer standards may harm operations and reputation
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 29.78 |
| Non-Institutional Investors (NIIs) | 4.99 |
| Retail Individual Investors (RIIs) | 1.39 |
| Employee | N/A |
| Total | 10.27 |